- Kaihao Lin, Lifang Huang, Yadong Wang, Kangkang Li, Yuanning Ye, Siqi Yang, Aimin Li. Efficacy of genotypic susceptibility‐guided tailored therapy for Helicobacter pylori infection: A systematic review and single arm meta‐analysis. Helicobacter 2023;28
- June Hwa Bae, Hyeong Ho Jo, Joong Goo Kwon, Eun Young Kim. Efficacy of 7-day Tailored Therapy for Helicobacter pylori Eradication based on Clarithromycin Resistance. Korean J Gastroenterol 2023;82:10
- Joon Sung Kim, Byung‐Wook Kim, Jin Il Kim, Woo Chul Chung, Sung Woo Jung, Chang Seok Bang, Gwang Ha Kim, Seon Woo Jeon, Moon Kyoung Joo, Si Hyung Lee, Yun Jeong Lim, Jae Kyu Sung, Seung Young Seo, Sun Young Park, Wan Sik Lee, Hang Lak Lee, Ki Bae Kim, Heung Up Kim. Empirical Therapy Versus Tailored Therapy of Helicobacter pylori in Korea: Results of the K‐CREATE Study. Helicobacter 2024;29
- Jung-Wook Kim, Albert C. Kim. Can Patients with Clarithromycin-Resistant Helicobacter pylori Infection Be Treated with a 7-Day Bismuth-Based Quadruple Therapy?. Gut and Liver 2024;18:931
- Jannis Kountouras. Considering the Long-Conflicting Topic of Empirical or Nonconventional Helicobacter pylori Eradication Regimens. Gut and Liver 2023;17:659
- Kyoungwon Jung, Sam Ryong Jee, Moon Won Lee, Myeongseok Koh, Su Jin Kim, Jin Lee, Moo In Park. Comparison of Helicobacter pylori eradication rates between 7 and 14 days of tailored therapy according to clarithromycin resistance test: A randomized, multicenter, non‐inferiority study. Helicobacter 2024;29
- Chul-Hyun Lim, Jung-Hwan Oh. Bismuth-Based Quadruple Therapy as First-Line Treatment for Clarithromycin-Resistant Helicobacter pylori Infection: A Prospective Randomized Comparison of 7- and 14-Day Treatment Regimens. Gut and Liver 2024;18:970
- Byung-Wook Kim. Helicobacter Infection in Clinical Practice. 2024.
